Global Skin Cancer Therapeutics Market Size, Trends, By Type (Melanoma and Non-Melanoma), By Therapy (Immunotherapy, Targeted Therapy, and Chemotherapy), By Distribution Channel (Hospitals Pharmacies, Drug Stores and Retail Pharmacies, and Online Providers), By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa): Global Opportunity Analysis and Industry Forecast, 2023-2030
Global Skin Cancer Therapeutics Market
The Global Skin Cancer Therapeutics Market was valued at US$ 7.9 Bn in 2022 estimated to reach US$ 14.1 Bn by 2030, with a CAGR of 6.84% from 2023-2030.
The most common type of cancer is skin cancer, which is brought on by the unchecked growth of abnormal skin cells. It happens when genetic defects or unrepaired DNA damage skin cells, causing uncontrolled cell proliferation in the skin.
The three main kinds of skin cancer are melanoma, basal cell carcinoma, and squamous cell carcinoma. Some of the common causes of skin cancer include sunlight, sunlamps, tanning beds, certain medical conditions, and drugs. Skin cancer is brought on by UV light, whether it be artificial or natural. Worldwide attention is being paid to early detection and treatment due to the disease's severity. Treatment options for skin cancer are numerous and include chemotherapy, targeted therapy, and immunotherapy.
Market Drivers
An increase in the prevalence of melanoma and non-melanoma cancer, a rise in the need for immunotherapy and targeted therapy-based therapies, and an increase in public knowledge of cancer treatment.
For instance, the American Cancer Society estimates that 5.4 million Americans will receive a diagnosis of basal and squamous skin cancer in 2020, and 2,000 will pass away from the disease. According to the same source, 3.3 million Americans are thought to have both types of skin cancer. Additionally, the development of improved medicines for the successful management of skin cancer is being aided by government programs as well as major companies in the production and development of these therapies.
Market Restraints
The lack of public awareness, stringent regulations, unfavorable treatment side effects, high cost, and availability of alternative treatments are some of the main barriers to the revenue growth of the skin cancer market. Growth will also be hampered by long-term side effects of skin cancer treatment, such as lung issues and skin color changes.
COVID-19 Impact
The COVID-19 outbreak is anticipated to harm the worldwide skin cancer therapy market. Patients experiencing difficulties while receiving treatment for skin cancer in hospitals were primarily due to the danger of infection. Almost every industry has been impacted by the COVID-19 worldwide public health catastrophe. As coronavirus outbreaks spread across the globe and force healthcare institutions to spend the majority of their budget combating COVID-19, the COVID-19 epidemic has led to a significant decline in demand for skin cancer treatment market remedies. During pandemics, patient visits to hospitals or diagnostic facilities for melanoma or non-melanoma skin cancer treatment are postponed because of the lockdown situation that followed the initial COVID-19 wave.
Market Segmentation
The scope of the Global Skin Cancer Therapeutics Market covers segmentation based on Type, Therapy, Distribution Channel, and Region.
Based on Type, the market is classified into Melanoma and Non-Melanoma.
Based on Therapy, the market is divided into Immunotherapy, Targeted Therapy, and Chemotherapy.
Based on Distribution Channel, the market is segmented into Hospitals Pharmacies, Drug Stores and Retail Pharmacies, and Online Providers.
Regional Analysis
The Global Skin Cancer Therapeutics Market is segmented into 5 main regions, namely, North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.
North America is estimated to hold the major market share during the forecast period due to the well-established healthcare infrastructure-focused market players in research and development (R&D) for cancer therapies, recent product launches, and the rising incidence of skin cancer. One of the top global life sciences businesses, Labcorp, debuted a novel assay for melanoma therapy choices in May 2022.
Lymphocyte-activation gene 3 (LAG-3) expression levels in tumor tissue can now be measured using the novel test using immunohistochemistry (IHC). LAG-3 is an immune-oncology target with proven clinical advantages in melanoma patients.
Key Developments
Nivolumab and relatlimab-rmbw (Opdualag, Bristol-Myers Squibb Company) were authorized by the US Food and Drug Administration in March 2022 for use in adult and pediatric patients with metastatic or unresectable melanoma who are 12 years of age or older. Relatilab and nivolumab, two antibodies that block the programmed death receptor-1 and LAG-3, are combined as Opdualag at a fixed dose.
In January 2022, SkinCure Oncology launched GentleCure.com, a consumer health education platform that offers evidence-based treatment options for basal cell (BCC) and squamous cell skin cancers (SCC). This platform focuses on providing a comprehensive model for the delivery of image-guided superficial radiotherapy (Image-Guided SRT)
.
Key Players
AB Science, Abbott Laboratories, Amgen, Inc., AstraZeneca PLC, Bristol-Myers Squibb Company, Castle Biosciences, Inc., Daiichi Sankyo Company, Limited, DermTech, F. Hoffmann-La Roche Ltd., GlaxoSmithKline PLC, Merck & Co., Inc., NeraCare GmbH, Novartis AG, Pfizer Inc., Qiagen NV, Sanofi SA, and Sun Pharmaceutical Industries Ltd.
Market Taxonomy
By Type
• Melanoma
• Non-Melanoma
By Therapy
• Immunotherapy
• Targeted Therapy
• Chemotherapy
By Distribution Channel
• Hospitals Pharmacies
• Drug Stores and Retail Pharmacies
• Online Providers
By Region
• North America
o U.S.
o Canada
o Mexico
• Latin America
o Brazil
o Argentina
o Colombia
o Peru
o Chile
o Venezuela
o Rest of Latin America
• Europe
o Germany
o France
o UK
o Russia
o Italy
o Spain
o Rest of Europe
• Asia Pacific
o China
o Japan
o India
o South Korea
o Australia
o New Zealand
o Singapore
o Malaysia
o Rest of Asia Pacific
• Middle East & Africa
o Saudi Arabia
o UAE
o Egypt
o Kuwait
o South Africa
o Rest Middle East & Africa
Key Questions Addressed by the Report
• What are the Key Opportunities in Global Bonsai Market?
• What will be the growth rate from 2023 to 2030?
• Which segment/region will have the highest growth?
• What are the factors that will impact/drive the Market?
• What is the competitive Landscape in the Industry?
• What is the role of key players in the value chain?
Global Skin Cancer Therapeutics Market
1 Introduction
1.1 Objective of the Study
1.2 Market Definition
1.3 Market Scope
2 Research Methodology
2.1 Data Mining
2.2 Validation
2.3 Primary Interviews
2.4 List of Data Sources
3 Executive Summary
4 Global Skin Cancer Therapeutics Market Outlook
4.1 Overview
4.2 Market Dynamics
4.2.1 Drivers
4.2.2 Restraints
4.2.3 Opportunities
4.2.4 Cumulative Impact due to recent Energy Crisis
4.2.5 Cumulative Impact due to nearing economic downturn.
4.2.6 Post covid-19 world Supply& Demand conditions
4.2.7 Cumulative Impact of Russia-Ukraine Conflict
4.3 Porters Five Force Model
4.4 Value Chain Analysis
5 Global Skin Cancer Therapeutics Market, By Type
5.1 Y-o-Y Growth Comparison, By Therapy and Services
5.2 Global Skin Cancer Therapeutics Market Share Analysis, By Type
5.3 Global Skin Cancer Therapeutics Market Size and Forecast, By Type
5.3.1 Melanoma
5.3.2 Non-Melanoma
6 Global Skin Cancer Therapeutics Market, By Therapy
6.1 Y-o-Y Growth Comparison, By Therapy
6.2 Global Skin Cancer Therapeutics Market Share Analysis, By Therapy
6.3 Global Skin Cancer Therapeutics Market Size and Forecast, By Therapy
6.3.1 Immunotherapy
6.3.2 Targeted Therapy
6.3.3 Chemotherapy
7 Global Skin Cancer Therapeutics Market, By Distribution Channel
7.1 Y-o-Y Growth Comparison, By Distribution Channel
7.2 Global Skin Cancer Therapeutics Market Share Analysis, By Distribution Channel
7.3 Global Skin Cancer Therapeutics Market Size and Forecast, By Distribution Channel
7.3.1 Hospitals Pharmacies
7.2.2 Drug Stores and Retail Pharmacies
7.2.3 Online Providers
8 Global Skin Cancer Therapeutics Market, By Region
8.1 Global Skin Cancer Therapeutics Market Share Analysis, By Region
8.2 Global Skin Cancer Therapeutics Market Size and Forecast, By Region
8.3 Global Skin Cancer Therapeutics Market Trends and Forecast, By Region
9 North America Skin Cancer Therapeutics Market Analysis and Forecast (2023-2030)
9.1 Introduction
9.2 North America Skin Cancer Therapeutics Market Share Analysis, By Type
9.3 North America Skin Cancer Therapeutics Market Size and Forecast, By Therapy
9.4 North America Skin Cancer Therapeutics Market Size and Forecast, By Distribution Channel
9.5 North America Skin Cancer Therapeutics Market Size and Forecast, By Country
9.5.1 U.S.
9.5.1.1 Market Size and Forecast, By Type
9.5.1.2 Market Size and Forecast, By Therapy
9.5.1.3 Market Size and Forecast, By Distribution Channel
9.5.2 Canada
9.5.2.1 Market Size and Forecast, By Type
9.5.2.2 Market Size and Forecast, By Therapy
9.5.2.3 Market Size and Forecast, By Distribution Channel
9.5.3 Mexico
9.5.3.1 Market Size and Forecast, By Type
9.5.3.2 Market Size and Forecast, By Therapy
9.5.3.3 Market Size and Forecast, By Distribution Channel
10 Europe Skin Cancer Therapeutics Market Analysis and Forecast (2023-2030)
10.1 Introduction
10.2 Europe Skin Cancer Therapeutics Market Share Analysis, By Type
10.3 Europe Skin Cancer Therapeutics Market Size and Forecast, By Therapy
10.4 Europe Skin Cancer Therapeutics Market Size and Forecast, By Distribution Channel
10.5 Europe Skin Cancer Therapeutics Market Size and Forecast, By Country
10.5.1 Germany
10.5.1.1 Market Size and Forecast, By Type
10.5.1.2 Market Size and Forecast, By Therapy
10.5.1.3 Market Size and Forecast, By Distribution Channel
10.5.2 France
10.5.2.1 Market Size and Forecast, By Type
10.5.2.2 Market Size and Forecast, By Therapy
10.5.2.3 Market Size and Forecast, By Distribution Channel
10.5.3 UK
10.5.3.1 Market Size and Forecast, By Type
10.5.3.2 Market Size and Forecast, By Therapy
10.5.3.3 Market Size and Forecast, By Distribution Channel
10.5.4. Russia
10.5.4.1 Market Size and Forecast, By Type
10.5.4.2 Market Size and Forecast, By Therapy
10.5.4.3 Market Size and Forecast, By Distribution Channel
10.5.5. Italy
10.5.5.1 Market Size and Forecast, By Type
10.5.5.2 Market Size and Forecast, By Therapy
10.5.5.3 Market Size and Forecast, By Distribution Channel
10.5.6 Spain
10.5.6.1 Market Size and Forecast, By Type
10.5.6.2 Market Size and Forecast, By Therapy
10.5.6.3 Market Size and Forecast, By Distribution Channel
10.5.7 Rest of Europe
10.5.7.1 Market Size and Forecast, By Type
10.5.7.2 Market Size and Forecast, By Therapy
10.5.7.3 Market Size and Forecast, By Distribution Channel
11 Asia Pacific Skin Cancer Therapeutics Market Analysis and Forecast (2023-2030)
11.1 Introduction
11.2 Asia Pacific Skin Cancer Therapeutics Market Share Analysis, By Type
11.3 Asia Pacific Skin Cancer Therapeutics Market Size and Forecast, By Therapy
11.4 Asia Pacific Skin Cancer Therapeutics Market Size and Forecast, By Distribution Channel
11.5 Asia Pacific Skin Cancer Therapeutics Market Size and Forecast, By Country
11.5.1 China
11.5.1.1 Market Size and Forecast, By Type
11.5.1.2 Market Size and Forecast, By Therapy
11.5.1.3 Market Size and Forecast, By Distribution Channel
11.5.2 Japan
11.5.2.1 Market Size and Forecast, By Type
11.5.2.2 Market Size and Forecast, By Therapy
11.5.2.3 Market Size and Forecast, By Distribution Channel
11.5.3 India
11.5.3.1 Market Size and Forecast, By Type
11.5.3.2 Market Size and Forecast, By Therapy
11.5.3.3 Market Size and Forecast, By Distribution Channel
11.5.4. South Korea
11.5.4.1 Market Size and Forecast, By Type
11.5.4.2 Market Size and Forecast, By Therapy
11.5.4.3 Market Size and Forecast, By Distribution Channel
11.5.5. Australia
11.5.5.1 Market Size and Forecast, By Therapy and Services
11.5.5.2 Market Size and Forecast, By Therapy
11.5.5.3 Market Size and Forecast, By Distribution Channel
11.5.6. New Zealand
11.5.6.1 Market Size and Forecast, By Type
11.5.6.2 Market Size and Forecast, By Therapy
11.5.6.3 Market Size and Forecast, By Distribution Channel
11.5.7 Singapore
11.5.7.1 Market Size and Forecast, By Type
11.5.7.2 Market Size and Forecast, By Therapy
11.5.7.3 Market Size and Forecast, By Distribution Channel
11.5.8. Malaysia
11.5.8.1 Market Size and Forecast, By Therapy and Services
11.5.8.2 Market Size and Forecast, By Therapy
11.5.8.3 Market Size and Forecast, By Distribution Channel
11.5.9 Rest of Asia
11.5.9.1 Market Size and Forecast, By Type
11.5.9.2 Market Size and Forecast, By Therapy
11.5.9.3 Market Size and Forecast, By Distribution Channel
12 Latin America Skin Cancer Therapeutics Market Analysis and Forecast (2023-2030)
12.1 Introduction
12.2 Latin America Skin Cancer Therapeutics Market Share Analysis, By Type
12.3 Latin America Skin Cancer Therapeutics Market Size and Forecast, By Therapy
12.4 Latin America Skin Cancer Therapeutics Market Size and Forecast, By Distribution Channel
12.5 Latin America Skin Cancer Therapeutics Market Size and Forecast, By Country
12.5.1 Brazil
12.5.1.1 Market Size and Forecast, By Type
12.5.1.2 Market Size and Forecast, By Therapy
12.5.1.3 Market Size and Forecast, By Distribution Channel
12.5.2 Argentina
12.5.2.1 Market Size and Forecast, By Type
12.5.2.2 Market Size and Forecast, By Therapy
12.5.2.3 Market Size and Forecast, By Distribution Channel
12.5.3. Colombia
12.5.3.1 Market Size and Forecast, By Type
12.5.3.2 Market Size and Forecast, By Therapy
12.5.3.3 Market Size and Forecast, By Distribution Channel
12.5.4. Peru
12.5.4.1 Market Size and Forecast, By Type
12.5.4.2 Market Size and Forecast, By Therapy
12.5.4.3 Market Size and Forecast, By Distribution Channel
12.5.5 Chile
12.5.5.1 Market Size and Forecast, By Type
12.5.5.2 Market Size and Forecast, By Therapy
12.5.5.3 Market Size and Forecast, By Distribution Channel
12.5.6 Venezuela
12.5.6.1 Market Size and Forecast, By Type
12.5.6.2 Market Size and Forecast, By Therapy
12.5.6.3 Market Size and Forecast, By Distribution Channel
12.5.7 Rest of Latin America
12.5.7.1 Market Size and Forecast, By Type
12.5.7.2 Market Size and Forecast, By Therapy
12.5.7.3 Market Size and Forecast, By Distribution Channel
13 Middle East Skin Cancer Therapeutics Market Analysis and Forecast (2023-2030)
13.1 Introduction
13.2 Middle East Skin Cancer Therapeutics Market Share Analysis, By Type
13.3 Middle East Skin Cancer Therapeutics Market Size and Forecast, By Therapy
13.4 Middle East Skin Cancer Therapeutics Market Size and Forecast, By Distribution Channel
13.5 Middle East Skin Cancer Therapeutics Market Size and Forecast, By Country
13.5.1 Saudi Arabia
13.5.1.1 Market Size and Forecast, By Type
13.5.1.2 Market Size and Forecast, By Therapy
13.5.1.3 Market Size and Forecast, By Distribution Channel
13.5.2 UAE
13.5.2.1 Market Size and Forecast, By Type
13.5.2.2 Market Size and Forecast, By Therapy
13.5.2.3 Market Size and Forecast, By Distribution Channel
13.5.3 Egypt
13.5.3.1 Market Size and Forecast, By Type
13.5.3.2 Market Size and Forecast, By Therapy
13.5.3.3 Market Size and Forecast, By Distribution Channel
13.5.4 Kuwait
13.5.4.1 Market Size and Forecast, By Type
13.5.4.2 Market Size and Forecast, By Therapy
13.5.4.3 Market Size and Forecast, By Distribution Channel
13.5.5 South Africa
13.5.5.1 Market Size and Forecast, By Type
13.5.5.2 Market Size and Forecast, By Therapy
13.5.5.3 Market Size and Forecast, By Distribution Channel
13.5.5 Rest of Middle East & Africa
13.5.6.1 Market Size and Forecast, By Type
13.5.6.2 Market Size and Forecast, By Therapy
13.5.6.3 Market Size and Forecast, By Distribution Channel
14 Competitive Analysis
14.1 Competition Dashboard
14.2 Market share Analysis of Top Vendors
14.3 Key Development Strategies
15 Company Profiles
15.1 AB Science
15.1.1 Overview
15.1.2 Offerings
15.1.3 Key Financials
15.1.4 Business Segment & Geographic Overview
15.1.5 Key Market Developments
15.1.6 Key Strategies
15.2 Abbott Laboratories
15.2.1 Overview
15.2.2 Offerings
15.2.3 Key Financials
15.2.4 Business Segment & Geographic Overview
15.2.5 Key Market Developments
15.2.6 Key Strategies
15.3 Amgen, Inc.
15.3.1 Overview
15.3.2 Offerings
15.3.3 Key Financials
15.3.4 Business Segment & Geographic Overview
15.3.5 Key Market Developments
15.3.6 Key Strategies
15.4 AstraZeneca PLC
15.4.1 Overview
15.4.2 Offerings
15.4.3 Key Financials
15.4.4 Business Segment & Geographic Overview
15.4.5 Key Market Developments
15.4.6 Key Strategies
15.5 Bristol-Myers Squibb Company
15.5.1 Overview
15.5.2 Offerings
15.5.3 Key Financials
15.5.4 Business Segment & Geographic Overview
15.5.5 Key Market Developments
15.5.6 Key Strategies
15.6 Castle Biosciences, Inc.
15.6.1 Overview
15.6.2 Offerings
15.6.3 Key Financials
15.6.4 Business Segment & Geographic Overview
15.6.5 Key Market Developments
15.6.6 Key Strategies
15. Daiichi Sankyo Company, Limited
15.7.1 Overview
15.7.2 Offerings
15.7.3 Key Financials
15.7.4 Business Segment & Geographic Overview
15.7.5 Key Market Developments
15.7.6 Key Strategies
15.8 DermTech
15.8.1 Overview
15.8.2 Offerings
15.8.3 Key Financials
15.8.4 Business Segment & Geographic Overview
15.8.5 Key Market Developments
15.8.6 Key Strategies
15.9 F. Hoffmann-La Roche Ltd.
15.9.1 Overview
15.9.2 Offerings
15.9.3 Key Financials
15.9.4 Business Segment & Geographic Overview
15.9.5 Key Market Developments
15.9.6 Key Strategies
